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Abstract
Sphingomyelin (SM) is an abundant phospholipid in cell membranes and in lipoproteins. In human plasma, SM is
mainly found in atherogenic lipoproteins; therefore, higher levels of SM may promote atherogenesis. We
investigated the relations between plasma SM levels and the presence of angiographic coronary heart disease
(CHD) and left ventricular systolic dysfunction. We studied 732 patients referred for coronary angiography. Median
SM levels were higher among patients with CHD and in those with LV systolic dysfunction (LVEF<50%) than in
patients without CHD or LV dysfunction. SM levels were significantly correlated with fibrinogen levels, diabetes,
apoB, and triglyceride levels. On multivariate analyses, higher median SM levels were associated with a higher risk
of CHD and lower LV ejection fraction. The pro-atherogenic property of plasma SM might be related to 1) CHD; 2)
LV systolic dysfunction; and 3) metabolism of apoB-containing or triglyceride-rich lipoproteins.
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Introduction
Sphingomyelin (SM), the second most abundant phos-
pholipid in mammalian plasma, is present in all major
lipoproteins. Up to 18% of total plasma phospholipid
exists as SM [1], with the ratio of phosphatidylcholine
(PC)/SM varying widely among lipoprotein subclasses
[2]. Atherogenic lipoproteins such as VLDL and LDL are
SM-enriched [1,3]. The SM content of atherosclerotic
lesions is higher than that of normal arterial tissue [4].
Williams and Tabas have suggested that subendothelial
retention and aggregation of atherogenic lipoproteins play
an important role in atherogenesis [5,6]. SM-rich LDL
retained in atherosclerotic lesions is acted on by an arterial
wall sphingomyelinase that appears to promote aggrega-
tion, initiating the early phase of atherosclerosis develop-
ment [7,8]. We have previously found that plasma SM
levels in ApoE KO mice are 4-fold higher than those in
WT mice [9], and this may partially explain the increased
atherosclerosis found in these animals [10]. Our laboratory
and others have also discovered that inhibition of SM bio-
synthesis significantly decreases plasma SM levels, thus
lessening atherosclerotic lesions in ApoE KO mice [11,12].
In case-control studies by Jiang et al [13] and Schlitt et
al [14], subjects with coronary heart disease (CHD) had
higher plasma SM levels than control subjects. In the
multi-ethnic study including 6814 subjects without clinical
CHD at baseline by Nelson et al, more extensive subclini-
cal atherosclerosis (carotid intimal-medial wall thickness,
ankle-arm blood pressure index, and Agatston coronary
artery calcium score) was associated with high plasma SM
levels[15]. However, in the same population, Yeboah et al
found plasma SM levels to be not predictive of incident
CHD events after 5 years of follow-up [16]. Therefore, the
question as to whether plasma SM is risk factor for CHD
remains controversial. In this study, we investigated poten-
tial associations between SM and the presence of angio-
graphic coronary heart disease (CHD) in a Chinese cohort.
Methods
Study Population: A total of 732 subjects who underwent
diagnostic coronary angiography for chest pain in Zhong-
shan Hospital between January, 2004 and December,
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any medium, provided the original work is properly cited.2005 were included in this study. Cardiovascular risk fac-
tors/diseases were obtained by clinical history. Coronary
heart disease (CHD) (n = 489) was predefined as the pre-
sence of a luminal diameter stenosis ≥5 0 %i na tl e a s t1
major coronary artery territory (left anterior descending,
left circumflex or right coronary artery or their major
branches). Among CHD patients, 388 had stable angina
pectoris (stable AP) and 101 had acute coronary syn-
drome (ACS). Non-CHD included subjects who had
<50% stenosis in all 3 coronary artery territories (n =
243). Exclusion criteria were evidence of significant con-
comitant cardiac and non-cardiac disease including
severe valvular heart disease, prior known cardiomyopa-
thy, malignancy, or febrile condition. Diabetes mellitus
was diagnosed by clinical history, use of hypoglycemic
medications or a fasting blood sugar level >7.0 mmol/L
(125 mg/dL); hypertension was defined in patients receiv-
ing antihypertensive treatment or with known diagnosis
of hypertension (blood pressure ≥140/90 mmHg). The
study was approved by the Institutional Review Board of
Zhongshan Hospital, Fudan University.
Laboratory Evaluation: The laboratory evaluation was
performed as described previously (17). Subjects were
instructed to fast for at least 8 hours prior to blood sam-
pling. Lipid profile was determined with Hitachi 7600
biochemistry autoanalyzer. Triglyceride (TG), total cho-
lesterol (TC) and high-density lipoprotein-cholesterol
(HDL-C) were measured with enzymatic methods (TG,
Shanghai Kehuadongling Diagnostics Co, Ltd; TC,
Shanghai Kehuadongling Diagnostics Co, Ltd; HDL-C,
PEG-modified enzyme HDL-C assay, Kyowa Medex Co).
Low-density lipoprotein-cholesterol (LDL-C) was calcu-
lated according to the Friedewald formula. ApoA-I, apoE,
apoB, and Lipoprotein(a) [Lp(a)] were determined by
immunoturbidimetric assays (apoA-I, apoE, and apoB,
DiaSyA Diagnostics; Lp(a), Nittobo Boseki Co Ltd).
Plasma SM measurement was performed as described
previously[17]. There were 4 steps to the enzymatic mea-
surement of plasma SM levels: 1) bacterial SMase hydro-
lyzed SM to phosphorylcholine and n-acylsphingosine; 2)
alkaline phosphatase generated choline from phosphoryl-
choline; 3) choline was then used to generate hydrogen
peroxide in a reaction catalyzed by choline oxidase; and
4) lastly, hydrogen peroxide was used together with
DAOS, 4-aminoantipyrine, and peroxidase, as a catalyst,
to generate a blue dye with an optimal absorption at 595
nm. The reaction buffer consisted of 0.05 M Tris-HCl
with 0.66 mM calcium chloride, pH 8. The following
enzyme concentrations present in a 50 ml reaction buf-
fer: 25 units of SMase, 500 units of alkaline phosphatase,
25 units of choline oxidase, and 1,000 units of peroxidase.
DAOS concentration was 0.73 mM, and 4-aminoantipyr-
ine concentration was 0.73 mM. Five microliters of
plasma was added to a 100 μl reaction buffer containing
enzymes, and after 45 min of incubation at 37°C, the
absorption was measured at 595 nm on a spectrophoto-
metric plate reader. The developed color remained con-
stant after the incubation time. Standard SM solution
(50 mg/dl) preparation (5 mg of SM) was dissolved in
10 ml of 2% Triton X-100 ethanol solution. Each sample
was measured in triplicate and the mean value was
presented.
Statistical Methods
Continuous variables were reported as median and 25-75
th
interquartile ranges if they were not normally distributed.
The distributions for plasma concentrations of SM were
skewed (p < 0.001) on both the Kolmogorov-Smirnova
and Shapiro-Wilks tests. Accordingly, SM levels are
reported as median and 25-75
th percentiles. For univariate
analyses, Spearman’s correlation was used to determine
correlations of SM with various atherosclerotic markers.
SM levels were also compared among the CHD and non-
CHD groups, among patients with and without diabetes,
and among the normal LV function and LV dysfunction
groups using the non-parametric Kruskal Wallis test.
Forced logistic regression was used to determine the rela-
tion between SM levels and the presence of CHD using
CHD as the dependent variable and SM levels, age, gender,
BMI, left ventricular ejection fraction (LVEF), diabetes,
smoking, HDL, TC, LDL, TG and hypertension as inde-
pendent variables. The same independent variables were
entered into a forced logistic model to identify predictors
of LV systolic dysfunction. In addition, linear regression
multivariate analysis was used to analyze predictors of
LVEF as a continuous variable. Selected interaction effects
were tested between the independent variables in the
model. All analyses were done using SPSS version 17 ana-
lytical software (SPSS Inc., Chicago, IL).
Results
A total of 732 subjects were included in the study, 489
had CHD. Among the patients with CHD, 101 patients
had ACS and 388 had stable AP. Clinical characteristics
of the subjects are described in Table 1. Median SM
levels were higher among patients with CHD than non-
CHD patients (47.2 vs 40.7 mg/dl, p < 0.001) (Figure 1A).
Of the total 732 patients included in the study, 619 had
assessment of LV systolic function. Among those with
LVEF, 86.1% had normal LVEF (>50%), 8.6% had mild
LV dysfunction (EF ranging between 40-49%), 3.4% had
moderate LV dysfunction (EF ranging between 30-39%),
and 1.9% had marked LV dysfunction (EF<30%). The
moderate and severe groups were grouped together
because of the small numbers of patients. Median SM
levels were higher among patients with LV systolic dys-
function (LVEF<50%) than in those with normal systolic
function (LVEF≥50%) (48.5 vs. 45.5 mg/dl, p = 0.001). As
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median SM levels in patients with normal, mild, and
moderate-severe degrees of LV dysfunction (45.5 mg/dL
vs. 47.3 mg/dL vs. 57.6 mg/dl, p = 0.021). When consid-
ered as a continuous variable, LVEF was significantly cor-
related with SM levels in all patients (r = -0.20, p <
0.001), in those with CHD (r = -0.15, p = 0.003), and in
those without CHD (r = -0.14, p = 0.046).
On univariate analyses, SM levels were significantly
correlated with triglyceride levels (r = 0.10, p = 0.005),
apoB (r = 0.13, p = 0.001), apoE (r = 0.135, p < 0.001),
fibrinogen levels (r = 0.11, p = 0.006), and LVEF (r =
-0.201, p < 0.001)(Table 2). There were no significant
correlations between SM levels and HDL cholesterol
(r = -0.069, p = 0.061), total cholesterol (r = 0.064, p =
0.089), or LDL cholesterol levels (r = 0.035, p = 0.35).
Median SM levels were higher for patients with diabetes
as compared to those without (47.1 vs. 45.2, p = 0.029).
Using multivariate logistic regression analysis including
age, gender, BMI, smoking, hypertension, diabetes, HDL,
LDL, TG, LV systolic dysfunction (LVEF<50%) and SM
levels, variables that were independently associated with
the presence of CHD were: age (p < 0.0001), male gender
(p < 0.0001), smoking (p = 0.002), diabetes (p = 0.004),
hypertension (p = 0.03), LVEF (p < 0.001) and SM (p <
0.001) (Table 3).
Using multivariate linear regression including the
same variables to predict LVEF as a continuous variable,
Table 1 Group comparisons between Non CHD and CHD as median (25-75 percentiles IQR) or percentage
Variable Non CHD CHD P value
Sphingomyelin(mg/dl) 40.7(33-50) 47.2(39-58) <0.001
Age(years) 59(53-67) 64(57-71) <0.001
BMI 24.7(22-26) 24.4(23-26) 1.0
LVEF(%) 69(64-73) 63(55-70) <0.001
Fibrinogen(mg/dl) 248(212-307) 294(236-356) <0.001
HDL-C(mmol/L) 1.1(0.9-1.2) 1.0(0.8-1.2) <0.001
LDL-C(mmol/L) 2.5(2.0-3.0) 2.6(2.1-3.0) 0.37
TC(mmol/L) 4.3(3.7-5.0) 4.3(3.8-4.9) 0.62
TG(mmole/L) 1.5(1.1-2.0) 1.5(1.1-2.2) 0.35
ApoA-I(g/L) 1.1(1.0-1.2) 1.1(0.9-1.2) 0.60
ApoB(g/L) 0.7(0.6-0.9) 0.8(0.6-0.9) 0.03
CHD, coronary heart disease; BMI, body mass index; LVEF, left ventricular ejection fraction; HDL, high density lipoprotein;
LDL, low density lipoprotein; TC, total cholesterol; TG, triglyceride; Apo, apolipoprotein.
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Figure 1 Median SM levels between CHD and non-CHD patients, and between patients with LV systolic dysfunction (LVEF<50%) and
controls (LVEF≥50%). Panel A, CHD vs Non-CHD; Panel B, LVEF<50% vs LVEF≥50%.
Chen et al. Nutrition & Metabolism 2011, 8:25
http://www.nutritionandmetabolism.com/content/8/1/25
Page 3 of 6LVEF was independently related to SM levels (p =
0.035) and a trend towards the presence of CHD (p =
0.052) (Table 4).
Discussion
In the present study, we found that SM levels were
independently associated with CHD, which was in line
with our previous observation [13]. Furthermore, we
reveal that plasma SM levels were correlated with LV
systolic dysfunction, and with plasma apoB and trigly-
cerides levels.
It is known that atherosclerosis is an inflammatory
disease. Inflammatory cells such as macrophages and
lymphocytes and inflammatory factors including cyto-
kines, chemokines and growth factors, promote focal
necrosis and advanced complicated lesion formation.
SM might act as a marker for an inflammatory effect in
the development and progression of CHD. Our sphingo-
myelin syntase (SMS) 2 mouse studies indicated that
SM biosynthesis is responsible for NF-Ba n dM A P
kinase-mediated inflammatory and atherosclerosis
[18,19]. We found that SMS2 deficiency substantially
diminished the abundance of toll like receptor 4
(TLR4)-MD2 complex levels on the surface of macro-
phages after LPS stimulation [18]. Moreover, we found
that SMS2 KO mice had less IL-6 and TNFa in the cir-
culation after LPS stimulation, compared with controls
[19].
The association between SM levels and LV dysfunction
is a novel finding as we are unaware of prior studies
reporting such a relation. Although CHD is a leading
c a u s eo fL Vs y s t o l i cd y s f u n c t i o n ,i ti su n l i k e l yt h a tt h e
SM-LVEF relation is mediated by CHD. SM levels were
similarly correlated in an inverse manner with LVEF in
both patients with and without CHD. In addition, the
relation between SM and LVEF remained significant
despite inclusion of CHD in the multivariate model. It
remains unclear as to whether higher plasma SM level is
a marker of LV dysfunction or whether SM is directly
involved in the pathogenesis of LV dysfunction. Alterna-
tively, higher SM levels may represent an adaptive
response to LV dysfunction. Inflammation is one of the
possible linkages. In our patient population, there was a
significant association between SM levels and fibrinogen,
an acute phase reactant in inflammation. Prior studies
have also found SM metabolism related to levels of CRP
[20], inflammatory marker. Inflammation is well known
to play a central role in the progression of LV dysfunc-
tion and heart failure [21]. Several lines of evidence sug-
gest that SM may play a role in the development of LV
dysfunction through promoting inflammation. In cardio-
myocytes, activation of the neutral sphingomyelinase,
which can hydrolyse SM, mediates TNFa-induced apop-
tosis and negative contractile effect[22-25]. Sphingomye-
linase levels have been shown to correlate with the
presence and severity of congestive heart failure [26].
Moreover, Mrnka et al. showed that SM concentration in
rat myocytes increased in resp o n s et op r e s s u r eo v e r l o a d ,
a well known precursor to LV hypertrophy and dysfunc-
tion [27]. We previously showed that sphingomyelin
synthase 2 (SMS 2), an enzyme directly involving in SM
Table 2 Univariate correlations of
sphingomyelin
Variable Sphingomyelin(mg/dl)
Fibrinogen r 0.107
P 0.006
LVEF r -0.201
P <0.001
ApoB r 0.126
P <0.001
ApoE r 0.135
P <0.001
TG r 0.104
P 0.005
LVEF, left ventricular ejection fraction; TG,
triglyceride; Apo, apolipoprotein.
Table 3 Logistic regression predictors of CHD
Variable P value aOR 95% CI
Sphingomyelin(mg/dl) <0.001 1.056 (1.04-1.08)
Age(years) <0.0001 1.062 (1.05-1.09)
Male gender <0.0001 0.383 (.25-.63)
Smoking 0.002 2.028 (1.3-2.99)
DM(history) 0.004 2.292 (1.66-4.78)
HTN(history) 0.03 1.596 (1.05-2.44)
HDL(mmol/L) 0.071 0.445 (.202-1.10)
TG(mmol/L) 0.085 0.981 (0.90-1.04)
LDL(mmol/L) 0.084 1.210 (.98-1.50)
LVEF(%) <0.001 0.033 (.005-.212)
CHD, coronary heart disease; DM, diabetes; HTN,
hypertension; TG, triglyceride; HDL, high density
lipoprotein; LDL, low density lipoprotein; LVEF, left
ventricular ejection fraction.
Table 4 Logistic regression predictors of LV
systolic dysfunction
Variable P value aOR 95%CI
Sphingomyelin(mg/dl) 0.035 1.02 (1.00-1.03)
Age(years) 0.885 0.99 (0.97-1.02)
Male gender 0.074 0.534 (.27-1.06)
Smoking 0.143 0.684 (.41-1.13)
DM(history) 0.618 1.160 (.65-2.07)
HTN(history) 0.309 0.772 (.47-1.27)
BMI 0.107 1.851 (.99-3.44)
CHD 0.052 0.540 (.29-1.00)
DM, diabetes; HTN, hypertension; BMI, body mass index; CHD,
coronary heart disease.
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membrane SM levels, reduces NFB-, MAP kinase-
mediated inflammatory responses, and thus reduces
atherosclerosis in mouse models[28,29]. However, there
are few prior data establishing the direct relationship
between plasma SM levels and LV dysfunction. This
study is the first one. It is quite possible that SM levels,
either in the blood or on the plasma membrane of car-
dio-muscle cells, play an important role in mediating LV
dysfunction. The detail mechanism is deserved for
further investigations.
In this study, we found the significant correlations
between plasma SM and apoB or triglycerides (Table 2).
It is well known that SM content is much higher in
apoB-containing or triglyceride-rich lipoproteins than in
HDL [1]. This may indicate that apoB-containing or tri-
glyceride-rich lipoproteins are atherogenic but that HDL
is not. It is also known that non-HDL lipoprotein sub-
endothelial retention is an early step in atherogenesis
[30]. It is believed that SM-rich non-HDL lipoproteins
retained in atherosclerotic lesions are hydrolyzed by an
arterial wall sphingomyelinase that promotes aggrega-
tion by converting SM to ceramide [5,31]. We have
shown that plasma SM levels can serve as a marker for
postprandial lipoprotein particle clearance [32]. If some-
how this clearance was blocked, the SM-rich particles
could likely be aggregated in the arterial wall after
encountering sphingomylinase there, and development
or instability of atheroscerotic plaques could be the con-
sequence. Tabas’s group provided convincing evidence
that apoE KO mice lacking sphingomyelinase have
decreased development of early atherosclerotic lesions
[8]. We investigated this retention/aggregation event in
another angle: reducing SM content of non-HDL lipo-
proteins through SMS deficient approach, thus leading
to less non-HDL lipoprotein retention/aggregation in
aorta, and preventing the development of atherosclerosis
[33].
This study has a number of limitations. First, the inde-
pendent relation of SM levels with LV systolic dysfunc-
tion should ideally be studied in the context of more
established biomarkers of LV systolic dysfunction, such
as BNP. Second, given the relatively small number of
patients with ACS (n = 101) in our study population, we
were unable to perform meaningful subgroup analyses
of the relation between SM levels and ACS. Third, the
size of the population was relatively small and the study
was not designed with a priori calculations with respect
to sample size or statistical power. As such, the findings
need to be confirmed in larger and prospectively
designed studies. Fourth, there is a difference in the age
of the two cohorts that were compared. The observed
changes in SM may reflect aging-associated differences.
Lastly, we used the definition of coronary stenoses as
defined>50% by coronary angiography as a crude marker
of hemodyanamically significant disease. Therefore, the
control group likely did have atherosclerosis. Although
numerous studies have used this criterion, quantification
of coronary atherosclerosis by intravascular ultrasound
i sam o r es e n s i t i v em e a s u r eo f atherosclerotic burden.
However, this technique was not performed in the
cohort evaluated in the present study.
In conclusion, in this study we found that the pro-
a t h e r o g e n i cp r o p e r t yo fp l a s m aS Mm i g h tb er e l a t e dt o
1) CHD; 2) LV systolic dysfunction; and 3) abnormal
metabolism of apoB-containing or triglyceride-rich
lipoproteins.
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